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Introduction
Colorectal cancer (CRC) is the second most common cause of cancer death in Europe, with 446,800 new CRC diagnoses and 214,700 disease-related deaths in 2012 [1] . Approximately 20% of the patients have metastatic disease at initial diagnosis, and an additional 30% to 40%
develop metastases during the course of the disease [2] . Twenty years ago, patients with metastatic colorectal cancer (mCRC) had a 5-year survival rate of only 11% [2] . Progress has been made through improvements in treatment, including targeted therapies. Anti-epidermal growth factor receptor monoclonal antibodies (anti-EGFR MAb) such as cetuximab and panitumumab have emerged as effective in a subset of mCRC patients and were initially approved in refractory mCRC, but then reported to be ineffective in tumours with mutations in codons 12 and 13 of exon 2 of the KRAS gene [3, 4] . In addition to the KRAS exon 2 mutation, in 2013 it was shown that mutations in KRAS exons 3 and 4, and in NRAS exons 2 to 4 had similar negative impact on anti-EGFR MAb efficacy [5] , and anti-EGFR MAbs were therefore restricted to mCRC patients without so-called "RAS mutations" (KRAS or NRAS mutations), improving target population definition.
In 2011, we conducted the French national Flash-KRAS study, showing that KRAS testing (exon 2 exclusively) was well-established in the management of mCRC patients in clinical practice in France, despite some regional discrepancies [6] . In 2014, we conducted the present Flash-RAS observational study to assess whether the genotyping tests were performed in accordance with the intervening changes in approved indications for anti-EGFR MAbs. The primary objective was to evaluate the prescription and implementation rates of RAS mutation testing in newly diagnosed mCRC patients (approved indication). Secondary objectives comprised analysis of reasons for non-prescription of testing, timing of the RAS testing 
Patients & Methods

Patient selection
This national multicentre non-interventional retrospective study was conducted with oncologists, gastroenterologists, and radiotherapists treating patients with mCRC in mainland
France. Participating physicians were to screen consecutive patients seen in daily practice satisfying the following criteria: age ≥18 years, with mCRC confirmed histologically after March 2014 (date at which the NRAS tests became available in France), seen in consultation between June 15th, 2014 and September 30th, 2014, and initiating or having initiated first-line therapy for mCRC during that period. The study complied with the principles of the Declaration of Helsinki and the international directives (ICH3) for non-interventional studies.
All participants gave oral consent prior to inclusion.
Data collection
Data were collected from patients' medical files and recorded in a questionnaire collecting 
NRAS/KRAS).
Simple KRAS mutation testing was requested for 9.2% of patients for whom a test was requested (31/338) ( Table 2 ). The most frequently used technique of enrichment of mutated RAS gene alleles was pyrosequencing/sequencing/snapshot (59.8%; 202/338).
Most patients (73.1%; 242/331) had a RAS/KRAS test request within 1 month around the diagnosis of metastatic disease. For 22.1% of patients (73/331), the test was requested more than 1 month after this diagnosis. It was requested before initiation of first-line therapy for 85.4% of patients for whom a test was requested and data were available (280/328) ( Table 2 ).
Desired location of Table 2
The oncogenetics platform was located outside the mCRC treatment centre for 80.7% of patients for whom a test was requested and data were available (268/332). The mean time between request for RAS/KRAS mutation testing and receipt of the results report was 24.6 ± 17.2 days (median: 20 days). The duration of the overall process is detailed in Table 3 60/66 patients) ( Figure 2 ). An anti-EGFR MAb (cetuximab, panitumumab) was prescribed for 10 of the 179 patients (5.6%) with a RAS mutation, despite the change in marketing The study showed that RAS mutation testing was routinely performed as part of mCRC patient management in 2014 in France. Compared to 2011, the rate of genotyping testing requests increased from 81.1% in the 2011 Flash-KRAS study [6] to 90.1% in the present study,
indicating clinical integration of anti-EGFR MAbs guidelines. For 9.2% of patients, mutation testing was requested for KRAS only, possibly because the study was conducted shortly after these recommendations were added to the cetuximab and panitumumab summaries of product characteristics [7, 8] .
In 2014, as previously observed in the 2011 Flash-KRAS study [6] , the test was prescribed early during mCRC patient management: within 1 month around the diagnosis of metastases in 73.1% of patients, and before initiation of first-line therapy in 85.4%. However, for 22.1% of the patients, the test was requested more than 1 month after diagnosis and, for 14.6%, after initiation of first-line therapy, which is not compatible with an informed choice of first-line treatment according to the patient's RAS status.
A mutation was identified in 59.7% of the patients, and mainly consisted in KRAS mutation.
In more than half of the patients, all 6 exons were analysed (KRAS exons 2, 3, and 4 plus NRAS exons 2, 3, and 4). Genotyping was in some cases conducted sequentially, and in 44 patients only KRAS exon 2 was analysed despite a request for full RAS genotyping, almost always because of early discovery of a KRAS exon 2 mutation. suggesting greater uniformity and coordination of mCRC patient management in the deployment of these new tests. This time interval was slightly shorter than reported in a previous French retrospective study [9] but remains long and hardly acceptable in clinical practice. The interval exceeded the maximum 10 working days recommended by European EQA schemes in 2013 [10] , the 7-to-10 working days recommended by the French National
Cancer Institute (INCa) in 2010 [11] , and the median 9 days (range: 4-21 days) specified in the summary of the activity of the French hospital molecular genetics platforms in 2012 [12] .
In a large study (2,510 tumour samples) performed in Germany from 2014 to 2016, 72% of RAS results were reported within 6 working days (lab turnaround time) [13] . In Canada, median turnaround time for EGFR results in lung cancer was 18 days (range: 15-26 days) in one study [14] , and 21 days in another in which EGFR and ALK mutation tests were performed after the first oncology consultation [15] . In the present study, time from dispatch to the technical platform to reception of the report was longer in 2014 (19. oncogenetics platform. This method may, therefore, expand the scope of personalized medicine for cancer patients.
In conclusion, this study showed that, in 2014, RAS mutation genotyping testing was a routine part of mCRC patient management in France. Compared to 2011, the rate of genotyping testing requests increased markedly. Overall, mCRC patient management was consistent with health authority guidelines, according to RAS status. However, the interval between test request and results feedback was longer than expected, and is not acceptable in clinical practice; this delay must be reduced. Standardization of assessment methods at European level could be a way to shorten this delay.
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